Buy Full Version
"Macular Edema Market"

Let us help you !

Invalid Email.

Please Select Country.

Invalid contact no.

Special Symbols Not Allowed.

Invalid Security Code.

Thank You For Your Interest.

We've Successfully Got Your Message,

Our Executive will get back to you Shortly.

Macular Edema Market by Type (Cystoid Macular Edema and Diabetic Macular Edema) and End User (Hospitals, Ophthalmic Clinics, Research Institutes, and Contract Research Organizations) - Global Opportunity Analysis and Industry Forecast, 2019-2026

Healthcare	LI_183546	Pages: NA	Jan 2020 \| 1532 Views
Author(s) : NA	Tables: NA	Charts: NA	Formats*:

Macular edema is a slowly progressing disease where accumulation of fluid takes place in a specialized part of the retina called the macula. Owing to the fluid retention in the retinal layer, the person may suffer from blurred or wavy central vision and/or change in appearance of colors. Most of macular edema cases are caused due to diabetes, wherein the blood vessels in the retina are usually damaged due to leakage of fluids, such as small amounts of blood. Other reasons that can lead to macular edema are side effects of certain medications, retinal vein occlusion, and certain genetic disorders, such as retinoschisis or retinitis pigmentosa.

Increase in the prevalence and incidence of diabetes has increased the risk of diabetic macular edema, making it the major driver of the market. Furthermore, increased use of off-label drugs, such as Avastin (bevacizumab) by Roche, and the emergence of new drugs in the market further boost the market growth. Moreover, recently two drugs Ozurdex manufactured by Allergan and Lucentis developed by Roche and Novartis, which are used for the treatment of macular edema, received regulatory approvals, thus boosting the market growth. Furthermore, rise in funding for the R&D activities to tackle the burden of these chronic diseases by medical organizations and pharmaceuticals companies boosts the market.

The global macular edema market is segmented based on type, end user, and region. Based on type, it is bifurcated into cystoid macular edema and diabetic macular edema. Based on end user, it is divided into hospitals, ophthalmic clinics, research institutes, and contract research organizations. Based on region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Comprehensive competitive analysis and profiles of major players, such as Acucela Inc., BCN Peptides, Aerie Pharmaceuticals, Inc., Aerpio Therapeutics, Inc., Amakem NV, Biomar Microbial Technologies, Antisense Therapeutics Limited, Charlesson LLC., Araim Pharmaceuticals, Inc., and Coherus BioSciences, are also provided in this report.

Key Benefits

This report provides an extensive analysis of the current and emerging market trends and dynamics through 2017-2023 in the global macular edema market to identify the prevailing market opportunities.
The projections in this report are made by analyzing the current trends and future market potential from 2017 to 2023, in terms of value.
Competitive intelligence helps to understand the competitive scenario across the geographies.
An in-depth analysis of current research and clinical developments within market is provided with key dynamic factors that help understand the market behavior.

Macular Edema Market Key Segments:

By Type

Cystoid Macular Edema
Diabetic Macular Edema

By End User

Hospitals
Ophthalmic Clinics
Research Institutes
Contract Research Organizations

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Taiwan
- Rest of Asia-Pacific
LAMEA
- Brazil
- Turkey
- Saudi Arabia
- South Africa
- Rest of LAMEA

CHAPTER 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

CHAPTER 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. MARKET SHARE ANALYSIS, 2016
3.4. PORTER’S FIVE FORCES ANALYSIS

3.4.1. MARKET DYNAMICS
3.4.2. Drivers
3.4.3. Restraints
3.4.4. Opportunities

CHAPTER 4 MACULAR EDEMA MARKET, BY TYPE

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. CYSTOID MACULAR EDEMA

4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast

4.3. DIABETIC MACULAR EDEMA

4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast

CHAPTER 5 MACULAR EDEMA MARKET, BY END USERS

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. HOSPITALS

5.2.1. Market size and forecast

5.3. OPHTHALMIC CLINICS

5.3.1. Market size and forecast

5.4. RESEARCH INSTITUTES

5.4.1. Market size and forecast

5.5. CONTRACT RESEARCH ORGANIZATIONS

5.5.1. Market size and forecast

CHAPTER 6 MACULAR EDEMA MARKET, BY GEOGRAPHY

6.1. OVERVIEW
6.2. NORTH AMERICA

6.2.1. Key market trends
6.2.2. Key growth factors and opportunities
6.2.3. Market size and forecast

6.2.3.1. U.S. market size and forecast
6.2.3.2. Canada market size and forecast
6.2.3.3. Mexico market size and forecast

6.2.4. North America Macular Edema Market By Type
6.2.5. North America Macular Edema Market by End Users

6.3. EUROPE

6.3.1. Key market trends
6.3.2. Key growth factors and opportunities
6.3.3. Market size and forecast

6.3.3.1. Germany market size and forecast
6.3.3.2. France market size and forecast
6.3.3.3. UK market size and forecast
6.3.3.4. Italy market size and forecast
6.3.3.5. Spain market size and forecast
6.3.3.6. Rest of Europe market size and forecast

6.3.4. Europe Macular Edema Market By Type
6.3.5. Europe Macular Edema Market by End Users

6.4. ASIA-PACIFIC

6.4.1. Key market trends
6.4.2. Key growth factors and opportunities
6.4.3. Market size and forecast

6.4.3.1. Japan market size and forecast
6.4.3.2. China market size and forecast
6.4.3.3. Australia market size and forecast
6.4.3.4. India market size and forecast
6.4.3.5. South Korea market size and forecast
6.4.3.6. Taiwan market size and forecast
6.4.3.7. Rest of Asia-Pacific market size and forecast

6.4.4. Asia-Pacific Macular Edema Market By Type
6.4.5. Asia-Pacific Macular Edema Market by End Users

6.5. LAMEA

6.5.1. Key market trends
6.5.2. Key growth factors and opportunities
6.5.3. Market size and forecast

6.5.3.1. Brazil market size and forecast
6.5.3.2. Turkey market size and forecast
6.5.3.3. Saudi Arabia market size and forecast
6.5.3.4. South Africa market size and forecast
6.5.3.5. Rest of LAMEA market size and forecast

6.5.4. LAMEA Macular Edema Market By Type
6.5.5. LAMEA Macular Edema Market by End Users

CHAPTER 7 COMPANY PROFILES

7.1. ACUCELA INC.

7.1.1. Operating business segments
7.1.2. Business performance
7.1.3. Key strategic moves and developments

7.2. BCN PEPTIDES

7.2.1. Operating business segments
7.2.2. Business performance
7.2.3. Key strategic moves and developments

7.3. AERIE PHARMACEUTICALS, INC.

7.3.1. Operating business segments
7.3.2. Business performance
7.3.3. Key strategic moves and developments

7.4. AERPIO THERAPEUTICS, INC.

7.4.1. Operating business segments
7.4.2. Business performance
7.4.3. Key strategic moves and developments

7.5. AMAKEM NV

7.5.1. Operating business segments
7.5.2. Business performance
7.5.3. Key strategic moves and developments

7.6. BIOMAR MICROBIAL TECHNOLOGIES

7.6.1. Operating business segments
7.6.2. Business performance
7.6.3. Key strategic moves and developments

7.7. ANTISENSE THERAPEUTICS LIMITED

7.7.1. Operating business segments
7.7.2. Business performance
7.7.3. Key strategic moves and developments

7.8. CHARLESSON LLC.

7.8.1. Operating business segments
7.8.2. Business performance
7.8.3. Key strategic moves and developments

7.9. ARAIM PHARMACEUTICALS, INC.

7.9.1. Operating business segments
7.9.2. Business performance
7.9.3. Key strategic moves and developments

7.10. COHERUS BIOSCIENCES

7.10.1. Operating business segments
7.10.2. Business performance
7.10.3. Key strategic moves and developments

With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
Technologically sophisticated and reliable insights through well audited and veracious research methodology
Sovereign research proceeds that present a tangible depiction of marketplace

With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

Patent and regulatory databases for understanding of technical & legal developments
Scientific and technical writings for product information and related preemptions
Regional government and statistical databases for macro analysis
Authentic new articles, web-casts and other related releases for market evaluation
Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast

Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

Validates and improves the data quality and strengthens research proceeds
Further develops analyst team’s market understanding and expertise
Supplies authentic information about market size, share, growth and forecasts

Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

Chief executives and VPs of leading corporations specific to industry
Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)

Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

Online Only ~~$3,456~~ $3,041 Data Pack/Excel ~~$3,840~~ $3,379 Single User License ~~$5,370~~ $4,726 Five User License ~~$6,450~~ $5,676 Enterprise User License ~~$8,995~~ $7,916

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,
Int'l : +1-503-894-6022
( Europe )
+ 44-845-528-1300
Drop us an email at
help@alliedmarketresearch.com